Syntaxin’s TSI are novel recombinant proteins designed to exploit the unique pharmacology inherent in bacterial botulinum neurotoxins
View how it works >
Syntaxin is a leader in botulinum toxin biology and applies its expertise to the identification of new therapeutic opportunities
View Patient Focus >
Syntaxin has an alliance with Allergan, Inc. the manufacturer of BOTOX® (onabotulinumtoxinA) and a world leader in the commercialisation of botulinum neurotoxin products to discover, develop and commercialise TSI for the treatment of pain in humans.
Syntaxin has two global alliances with Ipsen to explore the discovery and development of new therapeutic compounds utilising the natural diversity of botulinum neurotoxins.
08 May 2013
Syntaxin Hosting Biological Safety: Management and Practice Open Training Course, 13-14 June 2013
Syntaxin Hosting Biological Safety: Management and Practice Open Train...
29 March 2012
Melanie Lee, CEO of Syntaxin, joins the Board of Lundbeck
Oxford (UK), 29 March 2012 - Syntaxin, a biotechnology company special...
BioTrinity 2013 14-16 May 2013. Newbury, UK
Copyright © Syntaxin 2010
Designed & developed by Emperor